Clinical Trials
10
Active:0
Completed:5
Trial Phases
3 Phases
Phase 1:2
Phase 2:7
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 2
7 (70.0%)Phase 1
2 (20.0%)Not Applicable
1 (10.0%)Phase 2b Controlled Study of Dosing Techniques
Not Applicable
Recruiting
- Conditions
- Dry Eye Disease
- Interventions
- Drug: IVW-1001 Ophthalmic Eyelid Wipe
- First Posted Date
- 2025-08-24
- Last Posted Date
- 2025-08-24
- Lead Sponsor
- IVIEW Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT07140380
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma
Phase 1
Recruiting
- Conditions
- Primary Open-Angle Glaucoma (POAG)
- Interventions
- Drug: GVB-2001-high doseDrug: GVB-2001-low dose
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- IVIEW Therapeutics Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06921317
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- IVIEW Therapeutics Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06463678
IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease
Phase 1
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: IVW-1001 Ophthalmic Eyelid Wipe 0.1%Drug: IVW-1001 Ophthalmic Eyelid Wipe 0.2%Drug: IVW-1001 Placebo
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- IVIEW Therapeutics Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06400459
- Locations
- 🇺🇸
Houston Eye Associates, Houston, Texas, United States
Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis
Phase 2
Completed
- Conditions
- Acute Bacterial Conjunctivitis
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- IVIEW Therapeutics Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT05816070
- Locations
- 🇨🇳
Eye Hospital of Shandong First Medical University, Jinan, SHAN DONG, China
- Prev
- 1
- 2
- Next
News
No news found